TSN 084
Alternative Names: TSN-084Latest Information Update: 07 Jun 2023
At a glance
- Originator Tyligand Bioscience
- Class Antineoplastics; Small molecules
- Mechanism of Action Cyclin dependent kinase 19 inhibitors; Cyclin-dependent kinase 8 inhibitors; Protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Cancer
Most Recent Events
- 14 Apr 2023 Pharmacodynamics and adverse events data from a preclinical trial in cancer presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)
- 20 Jul 2022 Phase-I clinical trials in Cancer (Late-stage disease, Metastatic disease) in China (PO) (NCT06386705)
- 09 Jun 2022 TSN 084 is available for licensing as of 09 Jun 2022. https://tyligand.com/en/partnering.html